Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data
Our Score: 3/5 Our Score: 3/5 Wait
Industry Funding: From the study, Eli Lilly and Company sponsored the work and was involved in the study design, data collection, data review, data analysis, and drafting of the report
They check refrigerator temperature weekly
Hashimoto's and GLP-1 Microdosing Hashimoto's and GLP-1 Microdosing GLP-1 microdosing for Hashimoto's is a "low and slow" protocol that uses fractional doses of GLP-1 receptor agonists to reduce metabolic inflammation without triggering acute immune responses
2 with an extended n-terminus (orange), and a snapshot of the molecular dynamics simulations of Ex4-D-Ala with the receptor docked to the receptor-focused density map of Ex4-D-Ala conf
